Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.
D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications*; D004334:Drug Administration Schedule; D004427:Ear Diseases / Q000139:chemically induced*; D005260:Female; D006311:Hearing Disorders / Q000139:chemically induced; D006801:Humans; D008297:Male; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy*; D012141:Respiratory Tract Infections / Q000150:complications / Q000188:drug therapy*; D014031:Tobramycin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014031:Tobramycin